Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.
Konstantinopoulos PA, Cheng SC, Lee EK, da Costa AABA, Gulhan D, Wahner Hendrickson AE, Kochupurakkal B, Kolin DL, Kohn EC, Liu JF, Penson RT, Stover EH, Curtis J, Sawyer H, Polak M, Chowdhury D, D'Andrea AD, Färkkilä A, Shapiro GI, Matulonis UA.
Konstantinopoulos PA, et al. Among authors: liu jf.
JCO Precis Oncol. 2024 Apr;8:e2300635. doi: 10.1200/PO.23.00635.
JCO Precis Oncol. 2024.
PMID: 38635934
Clinical Trial.